Listening to Patients: Lessons Learned in the Development of Cancer Immunotherapy

Loading... Loading video...

Air date:	Wednesday, November 1, 2006, 3:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 132 * This only includes stats from October 2011 and forward.
Category:	WALS - Wednesday Afternoon Lectures
Runtime:	01:03:28
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	In the past two decades immunotherapy approaches have been shown to be effective for the treatment of selected patients with metastatic cancer. The administration of interleukin-2 or a monoclonal antibody against CTLA-4 can mediate regression of metastatic melanoma in about 15 percent of patients. The administration of in vitro expanded autologous anti-tumor T cells, plus IL-2, following a lymphodepleting chemotherapy results in objective regressions in 50 percent of patients with metastatic melanoma. T cells capable of mediating these regressions have been used to identify dozens of human cancer antigens. Recently gene therapy approaches that utilize the transduction of genes encoding anti-tumor T cell receptors has been shown to be effective and hold promise for the application of immunotherapy for the treatment of patients with common epithelial cancers. NIH Director's Wednesday Afternoon Lecture Series

NLM Title:	Listening to patients : lessons learned in the development of cancer immunotherapy / Steven A. Rosenberg.
Author:	Rosenberg, Steven A. National Institutes of Health (U.S.)
Publisher:
Subjects:	Immunotherapy Neoplasms--therapy
Publication Types:	Lecture Webcast
NLM Classification:	QZ 266
NLM ID:	101294005
CIT Live ID:	5176
Permanent link:	https://videocast.nih.gov/watch=5176

NIH VideoCasting